Evidence map›Paper›PMID 29057370›Full record

ArticleBiological psychiatry. Cognitive neuroscience and neuroimaging2017

Conditional Human Immunodeficiency Virus Transactivator of Transcription Protein Expression Induces Depression-like Effects and Oxidative Stress.

Jay P McLaughlin, Jason J Paris, Dionyssios Mintzopoulos, Kristen A Hymel, Jae K Kim, Thomas J Cirino, Timothy E Gillis, Shainnel O Eans, Gordana D Vitaliano, Jessica M Medina and 3 more

Open access · greenAbstract read
In one paragraph

Article in Biological psychiatry. Cognitive neuroscience and neuroimaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Expression of Human Immunodeficiency Virus Transactivator of Transcription (HIV-TatJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2022
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Jay P McLaughlinDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610.
Jason J ParisDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610.
Dionyssios MintzopoulosMcLean Imaging Center, Department of Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA 02478.
Kristen A HymelDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610.
Jae K KimMcLean Imaging Center, Department of Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA 02478.
Thomas J CirinoDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610.
Timothy E GillisMcLean Imaging Center, Department of Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA 02478.
Shainnel O EansDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610.
Gordana D VitalianoMcLean Imaging Center, Department of Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA 02478.
Jessica M MedinaDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610.
Richard C KrapfDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610.
Heather M StacyDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610.
Marc J KaufmanMcLean Imaging Center, Department of Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA 02478.
University of Florida · USHarvard University · USVirginia Commonwealth University · US

Funding

Training In Drug Abuse and Brain ImagingT32DA015036 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI SCOTT E LUKAS · 2002 to 2026
$5.3M
HIV Tat protein mediation of neurochemical changes and increased opioid rewardR01DA039044 · NIDA · UNIVERSITY OF FLORIDA · PI KAUFMAN, MARC J, MCLAUGHLIN, JAY P. · 2015 to 2019
$2.2M
Tat mediation of HIV-associated mood disorders via functional deficits in brainR01MH085607 · NIMH · UNIVERSITY OF FLORIDA · PI MCLAUGHLIN, JAY P. · 2011 to 2015
$2.1M
Preventing and Reducing HAND by Using New BDNF NanoprobesR44MH108481 · NIMH · EXQOR TECHNOLOGIES, INC. · PI VITALIANO, FRANCO, VITALIANO, GORDANA D. · 2018 to 2019
$1.3M
Nanoengineered Neuroprobes for MRI of Dopamine Transporters in Drug AddictionK08DA037465 · NIDA · MCLEAN HOSPITAL · PI VITALIANO, GORDANA D. · 2015 to 2018
$758k
Opiate abuse and sex steroids influence neuroAIDS pathologyR00DA039791 · NIDA · UNIVERSITY OF MISSISSIPPI · PI PARIS, JASON RICHARD · 2017 to 2019
$734k
ULTRA HIGH FIELD 9.4T ANIMAL MAGNETIC RESONANCE SCANNER: SUBSTANCE ABUSES10RR019356 · NCRR · MC LEAN HOSPITAL (BELMONT, MA) · PI KAUFMAN, MARC J · 2004 to 2004
$500k
Preventing and Reducing HAND by Using New BDNF NanoprobesR43MH108481 · NIMH · EXQOR TECHNOLOGIES, INC. · PI VITALIANO, FRANCO, VITALIANO, GORDANA D. · 2015 to 2016
$440k
Opiate abuse and sex steroids influence neuroAIDS pathologyK99DA039791 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI PARIS, JASON RICHARD · 2015 to 2016
$225k
New Targeted BDNF Nanoparticles for Treatment of Dopaminergic Neurodegeneration in METH Addiction and HANDR43DA044050 · NIDA · EXQOR TECHNOLOGIES, INC. · PI VITALIANO, FRANCO, VITALIANO, GORDANA D. · 2017 to 2017
$225k
NCRR NIH HHS S10 RR019356NIDA NIH HHS K08 DA037465NIDA NIH HHS K99 DA039791NIDA NIH HHS R00 DA039791NIDA NIH HHS R01 DA039044NIDA NIH HHS R43 DA044050NIDA NIH HHS T32 DA015036NIMH NIH HHS R01 MH085607NIMH NIH HHS R43 MH108481NIMH NIH HHS R44 MH108481
6 · The paper itself

Abstract

backgroundThe prevalence of major depression in those with HIV/AIDS is substantially higher than in the general population. Mechanisms underlying this comorbidity are poorly understood. HIV-transactivator of transcription (Tat) protein, produced and excreted by HIV, could be involved. We determined whether conditional Tat protein expression in mice is sufficient to induce depression-like behaviors and oxidative stress. Further, as oxidative stress is associated with depression, we determined whether decreasing or increasing oxidative stress by administering methylsulfonylmethane (MSM) or diethylmaleate (DEM), respectively, altered depression-like behavior.

methodsGT-tg bigenic mice received intraperitoneal saline or doxycycline (Dox, 25-100 mg/kg/day) to induce Tat expression. G-tg mice, which do not express Tat protein, also received Dox. Depression-like behavior was assessed with the tail suspension test (TST) and the two-bottle saccharin/water consumption task. Reactive oxygen/nitrogen species (ROS/RNS) were assessed ex vivo. Medial frontal cortex (MFC) oxidative stress and temperature were measured in vivo with 9.4-Tesla proton magnetic resonance spectroscopy (MRS).

resultsTat expression increased TST immobility time in an exposure-dependent manner and reduced saccharin consumption. MSM decreased immobility time while DEM increased it in saline-treated GT-tg mice. Tat and MSM behavioral effects persisted for 28 days. Tat and DEM increased while MSM decreased ROS/RNS levels. Tat expression increased MFC glutathione levels and temperature.

conclusionsTat expression induced rapid and enduring depression-like behaviors and oxidative stress. Increasing/decreasing oxidative stress increased/decreased, respectively, depression-like behavior. Thus, Tat produced by HIV may contribute to the high depression prevalence among those with HIV. Further, mitigation of oxidative stress could reduce depression severity.

Indexed as

glutathioneHIVmagnetic resonance spectroscopymajor depressionoxidative stressTattransgenic mice

Identifiers

PMID29057370
PMCPMC5648358
OpenAlexW2606444924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.